Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
California ICE Detention Center Found to Have Inadequate Medical Care, Court Monitor Says 
Gold Prices Rise as Fed Rate Hike Bets Ease 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
UK Retail Sales Rise as World Cup and Heatwave Boost Food, Pubs and Clothing 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Gold Prices Hold Near Seven-Week High as Markets Await U.S. Inflation Data 
U.S. Unseals Charges Against Five Alleged CJNG Leaders, Raises Reward for New Cartel Chief 
China vs. NASA: The New Moon Race and What's at Stake by 2030 
England Drought Expands to 71% as Heatwave Deepens Water Crisis 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
